This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Valneva SE

Drug Names(s): pseudomonas vaccine, VLA43, VLA 43

Description: IC43 is a Pseudomonas aeruginosa vaccine based on a recombinant fusion protein combining two Pseudomonas outer membrane proteins (OprF and OprI) that are highly conserved across all clinically relevant serotypes.

Deal Structure: The Pseudomonas product candidate was in-licensed to Pelias from Chiron. In January 2007, Intercell completed its acquisition of Pelias AG, gaining ownership of the Pseudomonas vaccine. In May 2013, Valneva announced its creation through the completion of the merger of equals between Vivalis and Intercell.

Intercell and Novartis
In July 2007, Intercell and Novartis announced that they agreed to form a major strategic partnership to accelerate innovation in vaccines development in infectious diseases. Eligible candidates include IC43 for prevention of hospital-acquired pseudomonas. Novartis is to assume responsibility for Phase III development, manufacturing and commercialization for any projects chosen after Phase II trials.

GlaxoSmithKline and Novartis
In April 2014, GSK and Novartis entered into a sale agreement under which GSK has agreed to sell, upon completion of the Transaction, the rights to GSKs currently marketed oncology portfolio,...See full deal structure in Biomedtracker

Partners: GlaxoSmithKline plc

VLA43 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug